株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

乳がん治療薬の米国市場・価格・用量・臨床パイプライン考察

US Breast Cancer Drug Market, Price, Dosage & Clinical Pipeline Insight 2025

発行 KuicK Research 商品コード 825268
出版日 ページ情報 英文 700 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=109.43円で換算しております。

ご注意: DRM (デジタル著作権管理システム) 付PDFになります。制限内容はお問合せください。
Multi-User License: 会社全体での使用権

Back to Top
乳がん治療薬の米国市場・価格・用量・臨床パイプライン考察 US Breast Cancer Drug Market, Price, Dosage & Clinical Pipeline Insight 2025
出版日: 2019年04月24日 ページ情報: 英文 700 Pages
概要

当レポートでは、米国の乳がん治療薬市場について調査分析し、市場機会、臨床パイプライン、上市薬、用量・価格の考察、市場力学などについて、体系的な情報を提供しています。

第1章 米国 - がんの発生率・有病率

第2章 米国の乳がん市場の情勢

第3章 米国の乳がん治療薬市場

  • 米国の乳がん治療薬市場の概要
  • 診断・スクリーニング市場シナリオ
  • 米国の乳がん臨床パイプラインの概要

第4章 乳がん治療薬市場の開発の見通し

  • ER陽性乳がん
  • HER2陽性乳がん
  • TNBC

第5章 米国 - 乳がん予防向け承認済み薬剤の用量・価格考察

  • Raloxifene Hydrochloride
  • Elvista
  • Tamoxifen Citrate

第6章 米国 - 乳がん治療向け承認済み薬剤の用量・価格考察

  • Abemaciclib
  • Abraxane (Paclitaxel Albumin-stabilized Nanoparticle Formulation)
  • Ado-Trastuzumab Emtansine
  • Afinitor (Everolimus)
  • Anastrozole
  • Aromasin (Exemestane)
  • Xeloda (Capecitabine)
  • Docetaxel (Docetaxel Anhydrous)
  • Doxorubicin Hydrochloride
  • Ellence (Epirubicin Hydrochloride)
  • Fluorouracil
  • Taxol (Paclitaxel)
  • Methotrexate
  • Cyclophosphamide

第7章 米国の乳がん治療薬市場力学

  • 市場促進要因
  • 課題

第8章 米国 - 乳がん治療薬市場の予測

  • 米国の乳がん治療薬市場の将来可能性
  • 来るべき薬剤分類の機会

第9章 米国 - 乳がん治療薬の臨床パイプライン:企業・相別

  • 研究
  • 前臨床
  • 臨床
  • 第I相
  • 第I/II相
  • 第II相
  • 第II/III相
  • 第III相
  • 登録前
  • 登録済み

第10章 米国 - 上市済みの乳がん治療薬の臨床考察:企業別

  • Afinitor
  • LYNPARZA
  • Abraxane
  • Verzenio
  • Kisqali
  • Lymphoseek
  • Kadcyla
  • Ibrance
  • Nerlynx
  • Soltamox
  • Tykerb
  • Zoladex
  • Omnitarg、Perjeta
  • Halaven
  • Taxotere
  • その他

第11章 競合情勢

  • Agilent Technologies
  • AstraZeneca
  • Bayer HealthCare Pharmaceuticals
  • Bristol-Myers Squibb
  • エーザイ
  • Eli Lilly
  • Novartis
  • Onyx Pharmaceuticals
  • Orion
  • Perrigo
  • Pfizer
  • Roche
目次
  • US Breast Cancer Drug Market Opportunity: US$ 20 Billion
  • US Breast Cancer Drug Clinical Pipeline by Company, Phase, Drug Class & Patient Segment
  • US Breast Cancer Marketed Drugs: 42 Drugs
  • US Breast Cancer Drug Clinical Pipeline: 317 Drugs
  • Dosage & Pricing Insight for Preventive & Treatment Drugs
  • US Breast Cancer Drug Market Dynamics

Breast cancer is the most commonly diagnosed cancer in American women. Breast cancer occurring in a woman under 40 is not a typical condition anymore. Changing lifestyle with numerous other factors like early menarche, late age at first childbirth, late menopause and prolonged exposure to endogenous oestrogens are surging the breast cancer drug market at a high rate. Also, short breast-feeding timeframe, rising of obesity in women after menopause, increasing rate of alcohol consumption in women, rising use of hormone replacement therapy (HRT) and oral birth control pills which causes increased levels of oestrogen are boosting the breast cancer drug market to its peak.

Various breast cancer therapeutics have come into existence like hormone drugs, chemotherapy drugs and targeted drugs. With advancements in drug delivery systems target specific therapies are prevailing. Also ER positive drugs for breast cancer are being introduced to the market. Drugs approved for prevention of breast cancer like Raloxifene Hydrochloride, Elvista etc. and drugs approved for the treatment of breast cancer like Abemaciclib, Abraxane, Xeloda, Taxol, Methotrexate etc. have been mentioned in detail with indication, dosing and pricing in our report on US Breast Cancer Drug Market.

US breast cancer drug market has high potency of growth with 42 drugs being commercially available and more than 300 of them being in the clinical pipeline. It is definitive that the market will grow due to the increase in prevalence of breast cancer and large group of geriatric population. Also, it has become a priority for researches and everyone linked to the healthcare system to find a cure for the second most commonly occurring disease. Even if the growth is slow it will increase exponentially in the near future.

Inaccessibility of the absolute treatment has given a wide scope of stage for the improvement of the US breast cancer drug market. Pharmaceutical companies are now concentrating on the improvement of new products which will be cost effective and will also have least side effects. Different organizations are also engaged with the advancement of specific types of molecules and novel therapies. These organizations have adapted the methodologies of the acquisitions, and furthermore propelling of the new products so as to endeavor in this huge and competitive market. Additionally, competition among new market players is likewise expected to expedite the growth for breast cancer drugs market in near future.

Table of Contents

1. US - Cancer Incidence & Prevalence

2. US Breast Cancer Market Landscape

  • 2.1 Incidence & Prevalence
  • 2.2 Diagnosis of Breast Cancer

3. US Breast Cancer Drug Market

  • 3.1 Overview US Breast Cancer Drug Market
  • 3.2 Diagnosis & Screening Market Scenario
  • 3.3 US Breast Cancer Clinical Pipeline Overview (Phase, Drug Class, Company, Patient Segment)

4. Forward Looking Developments in Breast Cancer Drug Market

  • 4.1 ER Positive Breast Cancer
    • 4.1.1 CDK4/6 Inhibitors
    • 4.1.2 PI3K Inhibitors
    • 4.1.3 Crizotinib for Lobular Breast Cancer
  • 4.2 HER2-Positive Breast Cancer
    • 4.2.1 Palbociclib & Herceptin (Spain)
    • 4.2.2 Tecentriq - FDA Approval for Breast Cancer
  • 4.3 Triple Negative Breast Cancer
    • 4.3.1 Atezolizumab & Nab-Paclitaxel
    • 4.3.2 Sacituzumab Govitecan
    • 4.3.3 Carboplatin & Docetaxel

5. US - Dosage & Pricing Insight for Drugs Approved for the Prevention of Breast Cancer

  • 5.1 Raloxifene Hydrochloride
  • 5.2 Elvista
  • 5.3 Tamoxifen Citrate

6. US - Dosage & Pricing Insight for Drugs Approved for the Treatment of Breast Cancer

  • 6.1 Abemaciclib
  • 6.2 Abraxane (Paclitaxel Albumin-stabilized Nanoparticle Formulation)
  • 6.3 Ado-Trastuzumab Emtansine
  • 6.4 Afinitor (Everolimus)
  • 6.5 Anastrozole
  • 6.6 Aromasin (Exemestane)
  • 6.7 Xeloda (Capecitabine)
  • 6.8 Docetaxel (Docetaxel Anhydrous)
  • 6.9 Doxorubicin Hydrochloride
  • 6.10 Ellence (Epirubicin Hydrochloride)
  • 6.11 Fluorouracil
  • 6.12 Taxol (Paclitaxel)
  • 6.13 Methotrexate
  • 6.14 Cyclophosphamide

7. US Breast Cancer Drug Market Dynamics

  • 7.1 Market Drivers
    • 7.1.1 Increasing Incidence of Breast Cancer
    • 7.1.2 Research & Development for Novel Drugs
    • 7.1.3 Increase in Healthcare Expenditure & Funding
    • 7.1.4 Increasing Breast Cancer Screening Programs
    • 7.1.5 Rising Consumption of Tobacco & Alcohol
  • 7.2 US Breast Cancer Drug Market Challenges
    • 7.2.1 Pricing Pressure Experienced by the Innovators
    • 7.2.2 High Cost associated with Drug Development & Clinical Trials
    • 7.2.3 Obstacles to the Incorporation of New Therapies for Breast Cancer

8. US - Breast Cancer Drug Market Forecast

  • 8.1 Future Potential of US Breast Cancer Drug Market
  • 8.2 Opportunities for Forthcoming Drug Classes

9. US - Breast Cancer Drug Clinical Pipeline by Company & Phase

  • 9.1 Research
  • 9.2 Preclinical
  • 9.3 Clinical
  • 9.4 Phase-I
  • 9.5 Phase-I/II
  • 9.6 Phase-II
  • 9.7 Phase-II/III
  • 9.8 Phase-III
  • 9.9 Preregistration
  • 9.10 Registered

10. US - Marketed Breast Cancer Drug Clinical Insight by Company

  • 10.1 Afinitor
  • 10.2 LYNPARZA
  • 10.3 Abraxane
  • 10.4 Verzenio
  • 10.5 Kisqali
  • 10.6 Lymphoseek
  • 10.7 Kadcyla
  • 10.8 Ibrance
  • 10.9 Nerlynx
  • 10.10 Soltamox
  • 10.11 Tykerb
  • 10.12 Zoladex
  • 10.13 Omnitarg, Perjeta
  • 10.14 Halaven
  • 10.15 Taxotere
  • 10.16 Other( 27 Drugs Profiles)

11. Competitive Landscape

  • 11.1 Agilent Technologies
  • 11.2 AstraZeneca
  • 11.3 Bayer HealthCare Pharmaceuticals
  • 11.4 Bristol-Myers Squibb
  • 11.5 Eisai Co Ltd
  • 11.6 Eli Lilly
  • 11.7 Novartis
  • 11.8 Onyx Pharmaceuticals
  • 11.9 Orion
  • 11.10 Perrigo
  • 11.11 Pfizer
  • 11.12 Roche

List of Figures

  • Figure 1-1: US - Estimated New Cancer Cases & Death (Number), 2019
  • Figure 1-2: US - Estimated New Cancer Cases & Death (Number), 2018
  • Figure 1-3: US - Estimated New Cancer Cases & Death in Women, (Number), 2019
  • Figure 1-4: US - Estimated New Cancer Cases & Death in Men (Number), 2019
  • Figure 1-5: US - Estimated New Cancer Cases & Death in Women (Number), 2018
  • Figure 1-6: US - Estimated New Cancer Cases & Death in Men (Number), 2018
  • Figure 1-7: US - Estimated New Cancer Cases in Men by Type (Number), 2019
  • Figure 1-8: US - Estimated New Cancer Cases in Men by Type (Number), 2018
  • Figure 1-9: US - Cancer Death Cases in Men by Type (Number), 2019
  • Figure 1-10: US - Cancer Death Cases in Men by Type (Number), 2018
  • Figure 1-11: US - Estimated New Cancer Cases in Women by Type (Number), 2019
  • Figure 1-12: US - Estimated New Cancer Cases in Women by Type (Number), 2018
  • Figure 1-13: US - Women Death by Cancer Type (Number), 2019
  • Figure 1-14: US - Women Death by Cancer Type (Number), 2018
  • Figure 2-1: US - Breast Cancer Cases in Women (Number), 2019
  • Figure 2-2: US - Invasive Breast Cancer Cases in Women & Men (Number), 2019
  • Figure 2-3: US - Risk of Developing Breast Cancer in Women by BRCA Genes (%), April' 2019
  • Figure 2-4: US - Risk of Developing Breast Cancer in Women & Men by BRCA2 (%), April' 2019
  • Figure 2-5: US - Genetic & Epigenetic Breast Cancer Prevalence in Women (%), April' 2019
  • Figure 2-6: US - Estimated New Breast Cancer Cases & Death (Number), 2019
  • Figure 2-7: US - Estimated New Breast Cancer Cases & Death in Women (Number), 2019
  • Figure 2-8: US - Estimated New Breast Cancer Cases & Death in Men, (Number), 2019
  • Figure 2-9: Global - Breast Cancer Occurance due to Genetic Abnormalities (Parents & Aging)
  • Figure 2-10: Procedures for Diagnosis of Breast Cancer
  • Figure 3-1: Different Screening Tests available for Breast Cancer
  • Figure 3-2: US Breast Cancer Clinical Pipeline By Phase (%), 2019 till 2025
  • Figure 3-3: US Breast Cancer Clinical Pipeline By Phase (Number), 2019 till 2025
  • Figure 3-4: US - Breast Cancer Clinical Pipeline By Mechanism of Action (%), 2019 till 2025
  • Figure 3-5: US - Breast Cancer Clinical Pipeline By Drug Class (%), 2019 till 2025
  • Figure 3-6: US - Breast Cancer Clinical Pipeline By Company (%), 2019 till 2025
  • Figure 3-7: US - Breast Cancer Clinical Pipeline By Patient Segment (%), 2019 till 2025
  • Figure 4-1: Ongoing Different Research Areas of Breast Cancer
  • Figure 5-1: Raloxifene Hydrochloride - Dosage for Osteoporosis & Breast Cancer, One Tablet Daily (Milligram)
  • Figure 5-2: Raloxifene Hydrochloride - Price per Tablet by Pack Size (US$/Tablet), April' 2019
  • Figure 5-3: Raloxifene Hydrochloride - Price per Pack Size (US$/Pack) April' 2019
  • Figure 5-4: Elvista - Dosage for Osteoporosis & Breast Cancer, One Tablet Daily (Milligram)
  • Figure 5-5: Elvista - Price per Tablet by Pack Size (US$/Tablet), April' 2019
  • Figure 5-6: Elvista - Price per Pack by Size (US$/Pack), April' 2019
  • Figure 5-7: Tamoxifen citrate - Price per Tablet by Pack Size for 10 Milligram Dose (US$/Tablet), April' 2019
  • Figure 5-8: Tamoxifen citrate - Cost of Different Quantities for 10 Milligram Dose (US$/Pack), April' 2019
  • Figure 5-9: Tamoxifen citrate - Cost of Different Quantities for 20 Milligram Dose (US$/Tablet), April' 2019
  • Figure 5-10: Tamoxifen citrate - Cost of Different Quantities for 20 Milligram Dose (US$/Pack), April' 2019
  • Figure 6-1: Verzenio (Abemaciclib) - Recommended Dosage (Combination Therapy vs Monotherapy) in Milligrams
  • Figure 6 2: Verzenio - Cost (US$)per Tablet across various Doses (Milligram), April'2019
  • Figure 6-3: Abraxene - Dosage via Intravenously (Milligram) & Cost for 1 powder of Injection (Milligram), (US$), April' 2019
  • Figure 6-4: Kadcyla (Ado-Trastuzumab Emtansine) - Cost per Unit (Milligram) of 1 powder (US$/Injection), April' 2019
  • Figure 6-5: Afinitor (Everolimus) - Cost of Different Units (Milligram) Dose (US$/Tablet), April' 2019
  • Figure 6-6: Afinitor (Everolimus) - Cost of Different Units (Milligram) Dose (US$/Pack), April' 2019
  • Figure 6-7: Anastrozole - Cost of Different Quantities for 1 Milligram Dose (US$/Tablet), April' 2019
  • Figure 6-8: Anastrozole - Cost of Different Quantities for 1 Milligram Dose (US$/Pack), April' 2019
  • Figure 6-9: Exemestane: Cost as per Quantity for 25 Milligram Dose Per Tablet vs Pack, (US$), April' 2019
  • Figure 6-10: Xeloda (Capecitabine) - Dosage as per Oral Intake (Milligram per Metre Square)
  • Figure 6-11: Xeloda - Cost of Different Quantities for 150 & 500 Milligram Dose (US$/Unit), April' 2019
  • Figure 6-12: Xeloda - Cost of Different Quantities for 150 & 500 Milligram Dose (US$/Pack), April' 2019
  • Figure 6-13: Docetaxel (Docetaxel Anhydrous) - Minimum & Maximum Dosage for Metaststic Breast Cancer (Milligram per Metre Square)
  • Figure 6-14: Docetaxel (Docetaxel Anhydrous) -Dosage for Node-Positive Breast Cancer (Milligram per Metre Square), Administered with Doxorubicin & Cyclophosphamide
  • Figure 6-15: Docetaxel - Price per Unit for Different Quantity (Millilitre) of 10 Milligram per Millilitre Intravenous Solution (US$), April' 2019
  • Figure 6-16: Docetaxel - Price per Pack for Different Quantity (Millilitre) of 10 Milligram per Millilitre Intravenous Solution (US$), April' 2019
  • Figure 6-17: Docetaxel - Price per Unit for Different Quantity (Millilitre) of 20 Milligram per Millilitre Intravenous Solution (US$), April' 2019
  • Figure 6-18: Docetaxel - Price per Pack for Different Quantity (Millilitre) of 20 Milligram per Millilitre Intravenous Solution (US$), April' 2019
  • Figure 6-19: Doxorubicin Hydrochloride - Price per Unit for Different Quantities of 2 Milligram per Millilitre Dose (US$), April' 2019
  • Figure 6-20: Doxorubicin Hydrochloride - Price per Pack for Different Quantities of 2 Milligram per Millilitre Dose (US$), April' 2019
  • Figure 6-21: Epirubicin - Price per Unit for Different Supply (Millilitre) of 2 Milligram per Millilitre Intravenous Solution (US$), April' 2019
  • Figure 6-22: Epirubicin - Price per Pack for Different Supply (Millilitre) of 2 Milligram per Millilitre Intravenous Solution (US$), April' 2019
  • Figure 6-23: Fluorouracil - Price per Unit for Different Supply (Millilitre) of 50 Milligram per Millilitre Intravenous Solution (US$), April' 2019
  • Figure 6-24: Fluorouracil - Price per Pack for Different Supply (Millilitre) of 50 Milligram per Millilitre Intravenous Solution (US$), April' 2019
  • Figure 6-25: Paclitaxel - Recommended v/s Adjusted Dosage (Milligram per Metre Square) intravenously
  • Figure 6-26: Taxol (Paclitaxel) - Price per Unit for Supply (Millilitre) of 6 Milligram per Millilitre Intravenous Solution (US$), April' 2019
  • Figure 6-27: Taxol (Paclitaxel) - Price per Pack for Supply (Millilitre) of 6 Milligram per Millilitre Intravenous Solution (US$), April' 2019
  • Figure 6-28: Methotrexate - Price per Unit for Injectable Powder (Gram) & Injectable Solution (Milligram per Millilitre) for Injection (US$), April' 2019
  • Figure 6-29: Methotrexate - Price per Tablet for Supply of 2.5 Milligram Dose (US$), April' 2019
  • Figure 6-30: Methotrexate - Price per Pack for Supply of 2.5 Milligram Dose (US$), April' 2019
  • Figure 6-31: Cyclophosphamide - Price per Unit for Supply of 1 Gram, 2 Gram & 5Milligram Dose for 1 Powder of Injection (US$), April' 2019
  • Figure 6-32: Cyclophosphamide - Price per Capsule for Supply of 25 & 50 Milligram Dose (US$), April' 2019
  • Figure 6-33: Cyclophosphamide - Price per Pack (100) for Supply of 25 & 50 Milligram Dose (US$), April' 2019
  • Figure 7-1: Drivers of Breast Cancer Drug Market
  • Figure 7-2: US - Estimation of Newly Diagnosed Cancers in Women, April' 2019
  • Figure 7-3: Challenges of Breast Cancer Drug Market
  • Figure 8-1: US - Breast Cancer Drug Market Opportunity (US$ Billion), 2019 - 2025

List of Tables

  • Table 6-1: Verzenio Dosage Modification for Adverse Reactions
  • Table 6-2: Regimens for Ellence (Epirubicin Hydrochloride Injection)
Back to Top